Abstract
Hematopoietic stem cell transplantation (HSCT) has become a potentially curative therapy for an increasing number of malignant and non-malignant conditions. As survival rates continue to improve, the focus of patient care has shifted from managing not only immediate but also long-term complications. Endocrine disorders are among the most prevalent late effects following HSCT. Detecting and treating such conditions offer new challenges, as well as opportunities to reduce preventable morbidity and mortality associated with HSCT. Our objective is to summarize recent literature and describe practical approaches to screening for and managing endocrine-related late effects. We focus on dyslipidemia, diabetes, thyroid disorders, osteoporosis, and hypogonadism. Mechanisms, monitoring, and management recommendations for each disorder are outlined. Growing data on these disorders in the post-transplant setting highlight the need for future study and evidence-based guidelines.
Article PDF
Avoid common mistakes on your manuscript.
References
Majhail, NS, Rizzo, JD. Surviving the cure: long term followup of hematopoietic cell transplant recipients. Bone Marrow Transplant 2013;48;1145–51.
Savani, BN, Griffith, ML, Jagasia, S, Lee, SJ. How I treat late effects in adults after allogeneic stem cell transplantation. Blood 2011;117;3002–9.
Martin, PJ, Counts Jr, GW, Appelbaum, FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 2010;28;1011–16.
Mohty, M, Apperley, JF. Long-term physiological side effects after allogeneic bone marrow transplantation. Hematol Am Soc Hematol Educ Program 2010;2010;229–36.
Mohty, B, Mohty, M. Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update. Blood Cancer J 2011;1;e16.
Chemaitilly, W, Sklar, CA. Endocrine complications of hematopoietic stem cell transplantation. Endocrinol Metab Clin North Am 2007;36;983–98; ix.
Tauchmanova, L, Selleri, C, Rosa, GD, et al. High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. Cancer 2002;95;1076–84.
Engelhardt, BG, Savani, U, Jung, DK, et al. New-onset post-transplant diabetes mellitus after allogeneic hematopoietic cell transplant is initiated by insulin resistance, not immunosuppressive medications. Biol Blood Marrow Transplant 2019;25; 1225–31.
Blaser, BW, Kim, HT, Alyea 3rd, EP, et al. Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012;18;575–83.
Premstaller, M, Perren, M, Kocack, K, et al. Dyslipidemia and lipid-lowering treatment in a hematopoietic stem cell transplant cohort: 25 years of follow-up data. J Clin Lipidol 2018;12;464–80 e463.
Marini, BL, Choi, SW, Byersdorfer, CA, Cronin, S, Frame, DG. Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patients. Biol Blood Marrow Transplant 2015;21; 809–20.
Armenian, SH, Sun, CL, Mills, G, et al. Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010;16;1138–44.
Tichelli, A, Bucher, C, Rovo, A, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood 2007;110;3463–71.
Tichelli, A, Passweg, J, Wojcik, D, et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the late effects working party of the European group for blood and marrow transplantation. Haematologica 2008;93;1203–10.
Bhatia, S, Armenian, SH, Landier, W. How I monitor long-term and late effects after blood or marrow transplantation. Blood 2017;130;1302–14.
Rotta, M, Storer, BE, Storb, R, et al. Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010; 16;1463–66.
Grundy, SM, Stone, NJ, Bailey, AL, et al. AHA/AC-C/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA /PCNA guideline on the management of blood cholesterol: executive summary: a report of the American college of cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018;73;3168–209.
McKenney, JM, Koren, MJ, Kereiakes, DJ, Hanotin, C, Ferrand, AC, Stein, EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012;59;2344–53.
Griffith, ML, Jagasia, MH, Misfeldt, AA, et al. Pretransplantation C-peptide level predicts early posttransplantation diabetes mellitus and has an impact on survival after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2011;17;86–92.
Griffith, ML, Jagasia, M, Jagasia, SM. Diabetes mellitus after hematopoietic stem cell transplantation. Endocr Pract 2010;16; 699–706.
Hammer, MJ, Casper, C, Gooley, TA, O’Donnell, PV, Boeckh, M, Hirsch, IB. The contribution of malglycemia to mortality among allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2009;15;344–51.
Baker, KS, Ness, KK, Steinberger, J, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood 2007;109;1765–72.
Shivaswamy, V, Boerner, B, Larsen, J. Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes. Endocr Rev 2016;37;37–61.
Sanders, JE, Hoffmeister, PA, Woolfrey, AE, et al. Thyroid function following hematopoietic cell transplantation in children: 30 years’ experience. Blood 2009;113;306–8.
Savani, BN, Koklanaris, EK, Le, Q, Shenoy, A, Goodman, S, Barrett, AJ. Prolonged chronic graft-versus-host disease is a risk factor for thyroid failure in long-term survivors after matched sibling donor stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2009;15;377–81.
Somali, M, Mpatakoias, V, Avramides, A, et al. Thyroid dysfunction in adult long-term survivors after hemapoeitic stem-cell transplantation (HSCT). Horm Metab Res 2005;37;494–99.
Sanchez-Ortega, I, Canals, C, Peralta, T, et al. Thyroid dysfunction in adult patients late after autologous and allogeneic blood and marrow transplantation. Bone Marrow Transplant 2012;47; 296–98.
Cohen, A, Bekassy, AN, Gaiero, A, et al. Endocrinological late complications after hematopoietic SCT in children. Bone Marrow Transplant 2008;41;S43–S48.
Savani, BN. Blood and marrow transplantation long-term management: prevention and complications. John Wiley & Sons; Chichester, UK 2013.
Cohen, A, Rovelli, A, Merlo, DF, et al. Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT late effects working party study. J Clin Oncol 2007; 25;2449–54.
Schimmer, AD, Mah, K, Bordeleau, L, et al. Decreased bone mineral density is common after autologous blood or marrow transplantation. Bone Marrow Transplant 2001;28;387–91.
Stern, JM, Sullivan, KM, Ott, SM, et al. Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. Biol Blood Marrow Transplant 2001;7;257–64.
Yao, S, McCarthy, PL, Dunford, LM, et al. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. Bone Marrow Transplant 2008;41;393–98.
Ebeling, PR. Approach to the patient with transplantation-related bone loss. J Clin Endocrinol Metab 2009;94;1483–90.
Savani, BN, Donohue, T, Kozanas, E, et al. Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007;13;517–20.
Weilbaecher, KN. Mechanisms of osteoporosis after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2000;6;165–74.
Tauchmanovà, L, Serio, B, Del Puente, A, et al. Long-lasting bone damage detected by dual-energy x-ray absorptiometry, phalangeal osteosonogrammetry, and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2002;87;5058–65.
Glotzbecker, B, Ho, VT, Aldridge, J, et al. Low levels of 25-hydroxyvitamin D before allogeneic hematopoietic SCT correlate with the development of chronic GVHD. Bone Marrow Transplant 2013;48;593–97.
Hansson, ME, Norlin, AC, Omazic, B, et al. Vitamin d levels affect outcome in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014;20;1537–43.
von Bahr, L, Blennow, O, Alm, J, et al. Increased incidence of chronic GvHD and CMV disease in patients with vitamin D deficiency before allogeneic stem cell transplantation. Bone Marrow Transplant 2015;50;1217–23.
Pundole, X, Cheema, HI, Petitto, GS, Lopez-Olivo, MA, Suarez-Almazor, ME, Lu, H. Prevention and treatment of bone loss and fractures in patients undergoing a hematopoietic stem cell transplant: a systematic review and meta-analysis. Bone Marrow Transplant 2017;52;663–70.
Majhail, NS, Rizzo, JD, Lee, SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther 2012;5; 1–30.
Cornillon, J, Vantyghem, MC, Couturier, MA, et al. Management of endocrine dysfunctions after allogeneic hematopoietic stem cell transplantation: a report of the SFGM-TC on dyslipidemia and thyroid disorders. Pathol Biol (Paris) 2013;61;168–70.
Ranke, MB, Schwarze, CP, Dopfer, R, et al. Late effects after stem cell transplantation (SCT) in children–growth and hormones. Bone Marrow Transplant 2005;35;S77–S81.
Salooja, N, Szydlo, RM, Socie, G, et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet 2001;358;271–76.
Author information
Authors and Affiliations
Corresponding author
Additional information
Peer review is under responsibility of the International Academy for Clinical Hematology
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Matthews, J., Eplin, D., Savani, B. et al. Managing Endocrine Disorders in Adults After Hematopoietic Stem Cell Transplantation. Clin Hematol Int 1, 180–188 (2019). https://doi.org/10.2991/chi.d.190917.001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/chi.d.190917.001